3B Blackbio DX Ltd · 532067
—
—
—
—
—
₹15 Cr
₹18 Cr
₹14 Cr
₹19 Cr
₹18 Cr
₹23 Cr
₹19 Cr
₹29 Cr
₹25 Cr
₹22 Cr
₹22 Cr
₹34 Cr
₹50 Cr
—
—
20-quarter listed-company comparison
Diagnostic Services Stocks in India
Diagnostic Services: Dr Lal Pathlabs Ltd owns the largest revenue base; 3B Blackbio DX Ltd has the fastest current growth.
The 3 Diagnostic Services companies listed in India are Dr Lal Pathlabs Ltd (₹30.7K Cr, the largest), 3B Blackbio DX Ltd and Chandan Healthcare Ltd. 1 of 3 covered companies beats NIFTY 500 on relative strength. Readings are as of 29 Sep 2026.
01 · the index people search for
Nifty Diagnostic Services Index — Constituents & Performance
All 3 listed Indian Diagnostic Services companies are named here, largest first — the same constituent set people search for as the Nifty Diagnostic Services index. Every figure is equal-weighted across those companies and carries its own as-of date. One large constituent cannot set the reading.
- Dr Lal Pathlabs Ltd₹30.7K Cr
- 3B Blackbio DX Ltd₹1.1K Cr
- Chandan Healthcare Ltd₹590 Cr
02 · sector relative strength, before individual stocks
Is Diagnostic Services outperforming NIFTY 500?
Diagnostic Services has outperformed NIFTY 500 by 4.4% over the last 52 weeks. Over 13 weeks the gap is a lead of 7.1%. 1 of 3 covered companies currently beats NIFTY on Mansfield relative strength, so leadership inside the sector is selective. Chandan Healthcare Ltd is the strongest against the sector itself at +5.4%. Readings are as of 2026-09-25.
+7.1%Sector vs NIFTY 500 · 13 weeks
+4.4%Sector vs NIFTY 500 · 52 weeks
1/3Stocks leading NIFTY 500
1/2Stocks leading sector
Sector metric: 18.1 as of 2026-09-25 · LEADERS · rising.
The central tension: the companies with the most scale are not necessarily the companies creating the most change.
Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.
Bottom line
Diagnostic Services has outperformed NIFTY 500 by 4.4% over 52 weeks and 7.1% over 13 weeks. 1 of 3 covered companies beat NIFTY on Mansfield relative strength, while 1 of 2 beat the sector itself. Dr Lal Pathlabs Ltd leads with revenue of ₹2,892 crore, based on 3 of 3 comparable companies through Jun 2026.
Companies
3
complete canonical membership
Combined market value
₹32.4K Cr
Dr Lal Pathlabs Ltd
Revenue growing
2/2
positive TTM year-on-year growth
Beating NIFTY 500
1/3
positive Mansfield relative strength
Comparing 3 of 3
03 · research priority, made explicit
4-Factor Sector Score
An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.
Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%
Dr Lal Pathlabs Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 57.3% evidence confidence.
How this score is built, and what the marks mean
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Dr Lal Pathlabs Ltd539524 | 62.2/100Thin evidence · provisional57% evidence | 17.7/35 Revenue 14.3% · PAT 5% · OPM change 2 pp 95% evidence | 22.0/25 ROCE 28% · OPM 31% 76% evidence | 10.0/20 P/E 54.6× · PEG — 0% evidence | 12.5/20 RS sector — · RS bench 17.6% · 1Y — 25% evidence | |
| Exact sum: 17.7 + 22 + 10 + 12.5 = 62.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2Chandan Healthcare LtdCHANDAN | 61.4/100Thin evidence · provisional54% evidence | TURNING | 17.9/35 Revenue — · PAT — · OPM change 3.8 pp 45% evidence | 21.5/25 ROCE 23.3% · OPM 24.2% 95% evidence | 10.0/20 P/E 22.4× · PEG — 0% evidence | 12.0/20 RS sector 5.4% · RS bench -5.8% · 1Y 7.2%0 of 11 weeks ahead 70% evidence |
| Exact sum: 17.9 + 21.5 + 10 + 12 = 61.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 33B Blackbio DX Ltd532067 | 54.2/100Thin evidence · provisional54% evidence | 21.6/35 Revenue 33.3% · PAT 20.8% · OPM change -16 pp 53% evidence | 19.6/25 ROCE 25.8% · OPM 43% 57% evidence | 10.0/20 P/E 19.6× · PEG — 35% evidence | 3.0/20 RS sector -10.6% · RS bench -9.8% · 1Y -5.1%7 of 12 weeks ahead to 2026-04-19 70% evidence | |
| Exact sum: 21.6 + 19.6 + 10 + 3 = 54.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
04 · what price has already done
Market action
Chandan Healthcare Ltd has the strongest one-year price move in Diagnostic Services at +7.2%. Dr Lal Pathlabs Ltd leads on Mansfield relative strength against NIFTY at +17.6%. 1 of 3 covered companies is above zero on that measure. Every line covers 313 weekly closes through 2026-09-25.
Price and relative strength
Every company, the sector's own index and NIFTY 500 all start level on the left edge of the window, so only the distance between the lines counts — the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.
How far ahead of or behind NIFTY 500 each company has been running, measured against its own recent average of that comparison, so the flat line at zero IS NIFTY 500: above it the company is beating the market, below it the market is beating the company. It opens on one year.
The same measure taken against Diagnostic Services itself instead of the whole market, so the flat line at zero is the sector: above it the company is beating its own peers, which is the sharper test of the two. It opens on one year.
05 · compare level, then change
Revenue Scale & Growth Durability
Dr Lal Pathlabs Ltd has the highest Revenue among the 3 Diagnostic Services companies compared here, at ₹2,892 crore. Chandan Healthcare Ltd is next at ₹289 crore. 3B Blackbio DX Ltd has the highest Revenue growth at 33.3%, so level and change sit with different companies. 3 of 3 companies report a comparable reading, the latest through Jun 2026.
What the numbers say: Dr Lal Pathlabs Ltd is the scale leader at ₹2,892 crore, 899.7% ahead of Chandan Healthcare Ltd. 3B Blackbio DX Ltd's growth is 33.3% from a ₹128 crore base, with 13 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.
LeaderDr Lal Pathlabs Ltd · ₹2,892 crore
Gap899.7% versus #2 · Chandan Healthcare Ltd
Persistence8/8 recent comparable periods
Coverage3/3 companies · 35 observations
Investor read: Dr Lal Pathlabs Ltd is the scale benchmark; 3B Blackbio DX Ltd is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.
This conclusion weakens if: Dr Lal Pathlabs Ltd's growth falls below 3B Blackbio DX Ltd's for two consecutive comparable reports while operating margin also compresses.
Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenuelargest
1Dr Lal Pathlabs Ltd 539524₹2.9K Cr
33B Blackbio DX Ltd 532067 · older report₹128 Cr
Revenue growthfastest growers
13B Blackbio DX Ltd 532067 · older report33%
2Dr Lal Pathlabs Ltd 53952414%
Revenue · company comparison
3/3 level · 2/3 change
On every company-comparison chart on this page: solid lines show level, dotted lines show change when “Both” is selected, and a missing report breaks the line rather than being invented.
All-company data · latest reported quarter
In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Revenue | Revenue growth | Reported |
|---|---|---|---|
| Dr Lal Pathlabs Ltd 539524 | ₹798 Cr | 19% | Jun 2026 |
| Chandan Healthcare Ltd CHANDAN | ₹81 Cr | 19% | Jun 2026 |
| 3B Blackbio DX Ltd 532067 | ₹50 Cr | 100% | Dec 2025 |
Full 20-quarter history · every available company
Revenue · reported quarter history
Chandan Healthcare Ltd · CHANDAN
—
—
—
—
—
—
—
—
—
—
—
—
—
₹55 Cr
₹63 Cr
₹68 Cr
₹68 Cr
₹65 Cr
₹76 Cr
₹81 Cr
Dr Lal Pathlabs Ltd · 539524
—
—
—
—
—
₹429 Cr
₹431 Cr
₹541 Cr
₹601 Cr
₹539 Cr
₹545 Cr
₹602 Cr
₹660 Cr
₹597 Cr
₹603 Cr
₹670 Cr
₹731 Cr
₹660 Cr
₹703 Cr
₹798 Cr
Revenue growth · reported quarter history
3B Blackbio DX Ltd · 532067
—
—
—
—
—
—
—
—
—
20%
28%
36%
53%
39%
-4.4%
16%
17%
100%
—
—
Chandan Healthcare Ltd · CHANDAN
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
19%
21%
19%
Dr Lal Pathlabs Ltd · 539524
—
—
—
—
—
—
—
—
—
26%
26%
11%
9.8%
11%
11%
11%
11%
11%
17%
19%
06 · compare level, then change
Operating Economics & Margin Trend
3B Blackbio DX Ltd has the highest OPM among the 3 Diagnostic Services companies compared here, at 43%. Dr Lal Pathlabs Ltd is next at 31%. Chandan Healthcare Ltd has the highest Margin change at +3.8 percentage points, so level and change sit with different companies. 3 of 3 companies report a comparable reading, the latest through Dec 2025.
What the numbers say: 3B Blackbio DX Ltd leads opm at 43%; Chandan Healthcare Ltd leads margin change at +3.8 percentage points.
Leader3B Blackbio DX Ltd · 43%
Gap38.7% versus #2 · Dr Lal Pathlabs Ltd
Persistence4/8 recent comparable periods
Coverage3/3 companies · 47 observations
Investor read: 3B Blackbio DX Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current margin change signal.
Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
OPMhighest
13B Blackbio DX Ltd 532067 · older report43%
2Dr Lal Pathlabs Ltd 53952431%
Margin changefastest expanders
2Dr Lal Pathlabs Ltd 539524+2.0 pp
33B Blackbio DX Ltd 532067 · older report−16.0 pp
Operating margin · company comparison
3/3 level · 3/3 change
All-company data · latest reported quarter
| Company | OPM | Margin change | Reported |
|---|---|---|---|
| 3B Blackbio DX Ltd 532067 | 43% | −16.0 pp | Dec 2025 |
| Dr Lal Pathlabs Ltd 539524 | 31% | +2.0 pp | Jun 2026 |
| Chandan Healthcare Ltd CHANDAN | 24% | +3.8 pp | Jun 2026 |
Full 20-quarter history · every available company
OPM · reported quarter history
3B Blackbio DX Ltd · 532067
39%
49%
32%
44%
53%
50%
41%
45%
41%
50%
43%
56%
55%
59%
35%
53%
43%
43%
—
—
Chandan Healthcare Ltd · CHANDAN
—
—
—
—
—
—
—
—
—
—
15%
—
18%
16%
16%
20%
21%
18%
15%
24%
Dr Lal Pathlabs Ltd · 539524
28%
22%
25%
23%
27%
24%
27%
27%
30%
26%
27%
28%
31%
26%
28%
29%
31%
27%
27%
31%
Margin change · reported quarter history
3B Blackbio DX Ltd · 532067
−31.7 pp
−10.0 pp
−12.9 pp
−11.4 pp
+13.6 pp
+1.5 pp
+8.8 pp
+0.7 pp
−12.0 pp
0.0 pp
+2.0 pp
+11.0 pp
+14.0 pp
+9.0 pp
−8.0 pp
−3.0 pp
−12.0 pp
−16.0 pp
—
—
Chandan Healthcare Ltd · CHANDAN
—
—
—
—
—
—
—
—
—
—
—
—
—
—
+1.4 pp
—
+2.9 pp
+1.9 pp
−1.2 pp
+3.8 pp
Dr Lal Pathlabs Ltd · 539524
−1.1 pp
−8.7 pp
−3.4 pp
−7.8 pp
−1.5 pp
+2.0 pp
+2.1 pp
+3.6 pp
+3.1 pp
+2.0 pp
0.0 pp
+1.0 pp
+1.0 pp
0.0 pp
+1.0 pp
+1.0 pp
0.0 pp
+1.0 pp
−1.0 pp
+2.0 pp
07 · compare level, then change
Profit Scale & Acceleration
Dr Lal Pathlabs Ltd has the highest Net profit among the 3 Diagnostic Services companies compared here, at ₹545 crore. 3B Blackbio DX Ltd is next at ₹58 crore. 3B Blackbio DX Ltd has the highest Profit growth at 20.8%, so level and change sit with different companies. Its Net profit series carries 15 reported observations across the 20-quarter window.
What the numbers say: Dr Lal Pathlabs Ltd leads with ₹545 crore of TTM profit, 839.7% above 3B Blackbio DX Ltd. 3B Blackbio DX Ltd shows 20.8% growth from a ₹58 crore profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.
LeaderDr Lal Pathlabs Ltd · ₹545 crore
Gap839.7% versus #2 · 3B Blackbio DX Ltd
Persistence6/8 recent comparable periods
Coverage3/3 companies · 35 observations
Investor read: Dr Lal Pathlabs Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.
Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profitlargest
1Dr Lal Pathlabs Ltd 539524₹545 Cr
23B Blackbio DX Ltd 532067 · older report₹58 Cr
Profit growthfastest growers
13B Blackbio DX Ltd 532067 · older report21%
2Dr Lal Pathlabs Ltd 5395245.0%
Net profit · company comparison
3/3 level · 2/3 change
All-company data · latest reported quarter
| Company | Net profit | Profit growth | Reported |
|---|---|---|---|
| Dr Lal Pathlabs Ltd 539524 | ₹170 Cr | 27% | Jun 2026 |
| 3B Blackbio DX Ltd 532067 | ₹22 Cr | 69% | Dec 2025 |
| Chandan Healthcare Ltd CHANDAN | ₹8 Cr | 28% | Jun 2026 |
Full 20-quarter history · every available company
Net profit · reported quarter history
3B Blackbio DX Ltd · 532067
—
—
—
—
—
₹8 Cr
₹5 Cr
₹7 Cr
₹8 Cr
₹9 Cr
₹9 Cr
₹11 Cr
₹15 Cr
₹13 Cr
₹8 Cr
₹13 Cr
₹15 Cr
₹22 Cr
—
—
Chandan Healthcare Ltd · CHANDAN
—
—
—
—
—
—
—
—
—
—
—
—
—
₹4 Cr
₹6 Cr
₹6 Cr
₹8 Cr
₹5 Cr
₹5 Cr
₹8 Cr
Dr Lal Pathlabs Ltd · 539524
—
—
—
—
—
₹63 Cr
₹71 Cr
₹84 Cr
₹111 Cr
₹82 Cr
₹86 Cr
₹108 Cr
₹131 Cr
₹98 Cr
₹156 Cr
₹134 Cr
₹152 Cr
₹91 Cr
₹132 Cr
₹170 Cr
Profit growth · reported quarter history
3B Blackbio DX Ltd · 532067
—
—
—
—
—
—
—
—
—
13%
80%
57%
88%
44%
-11%
18%
0.0%
69%
—
—
Chandan Healthcare Ltd · CHANDAN
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
8.1%
-18%
28%
Dr Lal Pathlabs Ltd · 539524
—
—
—
—
—
—
—
—
—
30%
21%
29%
18%
20%
81%
24%
16%
-7.1%
-15%
27%
08 · compare level, then change
Return On Capital Employed
Dr Lal Pathlabs Ltd has the highest ROCE among the 3 Diagnostic Services companies compared here, at 28%. 3B Blackbio DX Ltd is next at 25.8%. 3B Blackbio DX Ltd has the highest ROCE change at +5 percentage points, so level and change sit with different companies. 3 of 3 companies report a comparable reading, the latest through Jun 2026.
What the numbers say: Dr Lal Pathlabs Ltd leads ROCE at 28%, 2.2 percentage points above 3B Blackbio DX Ltd. 3B Blackbio DX Ltd has the strongest latest improvement at +5 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.
LeaderDr Lal Pathlabs Ltd · 28%
Gap8.5% versus #2 · 3B Blackbio DX Ltd
PersistenceNot enough history
Coverage3/3 companies · 0 observations
Investor read: Dr Lal Pathlabs Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current roce change signal.
ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
ROCEhighest
1Dr Lal Pathlabs Ltd 53952428%
23B Blackbio DX Ltd 532067 · older report26%
ROCE changefastest improvers
13B Blackbio DX Ltd 532067 · older report+5.0 pp
2Dr Lal Pathlabs Ltd 539524−1.0 pp
Return on capital · company comparison
3/3 level · 3/3 change
All-company data · latest reported quarter
| Company | ROCE | ROCE change | Reported |
|---|---|---|---|
| Dr Lal Pathlabs Ltd 539524 | 28% | −1.0 pp | Jun 2026 |
| 3B Blackbio DX Ltd 532067 | 26% | +5.0 pp | Dec 2025 |
| Chandan Healthcare Ltd CHANDAN | 23% | −6.0 pp | Jun 2026 |
Full 20-quarter history · every available company
No consistent historical series is available for roce.
No consistent historical series is available for roce change.
09 · compare level, then change
Valuation Against Growth & Quality
No company in this Diagnostic Services comparison reports a valuation figure this section can compare, so the PEG rank is empty. On P/E, 3B Blackbio DX Ltd is lowest at 19.6×, across 3 of 3 companies with a usable reading. PEG asks what price is being paid for growth; P/E keeps that answer anchored to the actual earnings multiple.
What the numbers say: There is not enough comparable evidence to name a reliable peg leader.
LeaderNo comparable leader
GapNot enough peers
PersistenceNot enough history
Coverage0/3 companies · 0 observations
Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.
This conclusion weakens if: The next two comparable reports reverse the current p/e signal.
PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.
PEGlowest PEG
—Not enough comparable data—
P/Elowest P/E
13B Blackbio DX Ltd 532067 · older report19.6
3Dr Lal Pathlabs Ltd 53952454.6
Valuation · company comparison
0/3 level · 3/3 change
All-company data · latest reported quarter
| Company | PEG | P/E | Reported |
|---|---|---|---|
| 3B Blackbio DX Ltd 532067 | — | 24.4 | Dec 2025 |
| Dr Lal Pathlabs Ltd 539524 | — | 53.9 | Jun 2026 |
| Chandan Healthcare Ltd CHANDAN | — | 24.4 | Jun 2026 |
Full 20-quarter history · every available company
No consistent historical series is available for peg.
P/E · reported quarter history
3B Blackbio DX Ltd · 532067
4.0
8.0
9.3
8.8
13.0
15.6
13.4
12.7
20.9
21.4
20.2
27.6
30.0
39.7
28.9
25.8
23.9
24.4
—
—
Chandan Healthcare Ltd · CHANDAN
—
—
—
—
—
—
—
—
—
—
—
—
—
—
22.2
22.9
25.6
29.2
22.0
24.4
Dr Lal Pathlabs Ltd · 539524
82.2
78.8
59.9
49.0
77.4
76.0
62.6
78.8
79.8
71.3
57.2
64.9
71.6
61.4
49.7
47.9
52.1
44.0
40.5
53.9
10 · before the conclusion, check the blind spots
What can make this comparison misleading?
This Diagnostic Services comparison names 6 specific ways its own evidence can mislead, all listed below. 1 of the 3 companies reports on an older date than the sector's freshest reporters, so its rank is marked stale. 1 of the 5 ranked sections has fewer than three usable current readings. A high growth rate can still be a low-base artefact.
Keep these limits visible
- A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
- A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
- The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
- An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
- 1 company has an older fundamental reporting date than the sector’s freshest reporters; its rank carries a stale marker.
- Thin comparisons: Valuation have fewer than three usable current readings.
11 · evidence and freshness
How was this comparison built?
This comparison is built from the reported filings of 3 Diagnostic Services companies, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Jun 2026 and market data through 2026-09-25. A second data feed fills gaps only after identity and scale reconciliation, and missing observations are never interpolated.
FundamentalsThrough Jun 2026 · up to 20 quarters per company
Market dataThrough 2026-09-25 · weekly price and relative-strength history
Derived metricsGrowth, changes and PEG are calculated only when their inputs are comparable.
Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.
Source standing0 cross-checked · 3 unverified · 0 withheld, of 3 graded companies.
How a second data feed is admitted, and what happens when it disagrees
A second feed is read only after its reported income is matched against the primary source on at least three overlapping periods. Where the two agree the figures fill silently. Where there is too little shared history to compare, the figures are still drawn — they are the only evidence there is — and marked ⚠ unverified everywhere they appear. Where the two are known to disagree, nothing from the second feed is drawn and the affected company is named under the chart it is missing from.
12 · questions investors ask, short speakable answers
Diagnostic Services company comparison FAQs
These 21 answers restate the Diagnostic Services comparison above in question form. Every one is computed from the same 3 companies and the same reported filings as the rankings and charts, current through Jun 2026. Price and relative-strength answers run through 2026-09-25. Nothing here is estimated, and none of it is a recommendation.
Is the Diagnostic Services sector outperforming NIFTY 500?
Diagnostic Services has outperformed NIFTY 500 by 4.4% over 52 weeks and 7.1% over 13 weeks. 1 of 3 covered companies beat NIFTY on Mansfield relative strength, while 1 of 2 beat the sector itself.
Which Diagnostic Services company is largest by revenue?
Dr Lal Pathlabs Ltd leads with revenue of ₹2,892 crore, based on 3 of 3 comparable companies through Jun 2026.
Which Diagnostic Services company is growing fastest?
3B Blackbio DX Ltd has the fastest current revenue growth at 33.3%, across 2 of 3 comparable companies.
Which Diagnostic Services company has the strongest 4-Factor Sector Score?
Dr Lal Pathlabs Ltd ranks first at 62.2/100 with 57.3% evidence confidence. The score prioritizes research; it is not a buy recommendation.
How much history does this Diagnostic Services comparison include?
The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.
How is the 4-Factor Sector Score calculated?
The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.
Is there a Nifty Diagnostic Services index?
NSE India maintains Nifty indices for several broad sector categories — Nifty Bank, Nifty IT, Nifty Pharma and others — but not for every sub-sector grouping on this site. Whether or not an official Nifty index covers Diagnostic Services, this page builds its own equal-weight basket of 3 listed Diagnostic Services companies — one company, one vote, regardless of market value — so no single large company dominates the reading. Figures are as of Jun 2026.
Which are the best Diagnostic Services stocks in India?
Ranked by this page's four-factor score, Dr Lal Pathlabs Ltd places first among 3 listed Diagnostic Services companies, followed by Chandan Healthcare Ltd. That is a ranking of published data — earnings, quality, valuation and market behaviour as of Jun 2026 — and not a recommendation; Sector Alpha is not registered with SEBI as an investment adviser.
How many Diagnostic Services stocks are listed in India?
This comparison covers 3 listed Diagnostic Services companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Jun 2026.
Which Diagnostic Services company is the biggest?
Dr Lal Pathlabs Ltd is the largest, with trailing-twelve-month revenue of ₹2,892 crore, ahead of Chandan Healthcare Ltd at ₹289 crore. That covers 3 of 3 companies with comparable reporting through Jun 2026.
Which Diagnostic Services company has the best profit margins?
3B Blackbio DX Ltd has the highest operating margin at 43%, from 3 of 3 comparable companies. Chandan Healthcare Ltd shows the biggest recent improvement, at +3.8 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.
Which Diagnostic Services company makes the most profit?
Dr Lal Pathlabs Ltd earns the most, at ₹545 crore of trailing-twelve-month net profit, from 3 of 3 comparable companies. 3B Blackbio DX Ltd has the fastest profit growth at 20.8%, though growth off a small or recovering profit base overstates how much has actually changed.
Which Diagnostic Services company earns the highest return on capital?
Dr Lal Pathlabs Ltd leads on return on capital employed at 28%, across 3 of 3 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.
Is the Diagnostic Services sector beating the market?
Diagnostic Services has outperformed NIFTY 500 by 4.4% over the last 52 weeks and 7.1% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 1 of 3 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.
Which Diagnostic Services stock has the strongest price momentum?
Dr Lal Pathlabs Ltd has the strongest relative strength against NIFTY 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.
Which Diagnostic Services company scores highest for research priority?
Dr Lal Pathlabs Ltd scores 62.2 out of 100 with 57.3% evidence confidence, from 17.7 points on growth and earnings, 22 on capital efficiency, 10 on valuation and 12.5 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.
How many Diagnostic Services companies does this comparison cover, and over what period?
It compares 3 listed companies over up to 20 reported quarters of fundamentals, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.
What is the total market cap of the Diagnostic Services sector?
The 3 Diagnostic Services companies on this page carry ₹32,388 crore of combined market value. Dr Lal Pathlabs Ltd is the largest at ₹30,674 crore, about 95% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-09-29.
How is the Diagnostic Services sector performing?
1 of the 3 covered Diagnostic Services companies are beating NIFTY 500 on Mansfield relative strength. The sector itself is 4.4% ahead of NIFTY 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-09-29.
Why are some values on this page blank?
A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.
Is this investment advice?
No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.
Not SEBI Registered !! Not Investment advice !!